Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurologica
NEW YORK -- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 µg in adults with major depressive disorder (MDD). Read More
Đọc thêm từ Tài chính
Nie Huihua on the non-Westernness of Chinese government and the challenge to innovation
Nie Huihua, a professor of economics at Renmin University, discusses how an effective understanding of China’s development requires a shift from Western-centric frameworks to an integrated perspective that recognises how formal institutions, informal grass-roots mechanisms and cu
Is Now a Good Time to Buy Tilray Brands Stock?
Tilray Brands' (NASDAQ: TLRY) stock rose dramatically after its initial public offering, then plunged, tracking the broader marijuana sector's rise and fall. The huge growth that Wall Street had hoped for simply didn't materialize, and investors moved on. But Tilray is still arou
China-Asean relations are bigger than mere geopolitics
China-Asean relations are usually described in two ways. One emphasises danger: the South China Sea, US-China rivalry, military pressure and risk of Southeast Asia being pulled into China’s orbit. The other emphasises opportunity: trade, infrastructure, investment, supply chains
